FDA approves betrixapan for extended DVT/PE prophylaxis

The US Food and Drug Administration (FDA) approved betrixaban (Bevyxxa), a new oral anticoagulant for prevention of venous thromboembolism (VTE) in hospitalized medical patients with risk factors for DVT/PE. With betrixaban, manufacturer Portola will seek to expand a tiny market niche it could immediately dominate: prophylaxis of DVT/PE extending for about a month after hospital [… read more]

The post FDA approves betrixapan for extended DVT/PE prophylaxis appeared first on PulmCCM.

Source: PulmCCM

Leave a Reply